YAFO Acts as Exclusive Financial Advisor for Rhizen Pharmaceuticals in its Licensing-out Transaction with Curon Biopharma

雅法担任Rhizen Pharmaceuticals独家顾问,完成与同润生物商业许可交易

Despite the COVID-19 challenges, we are happy to announce YAFO's 3rd major cross-border transaction in the last 6 months!


Click here to view the last 2 transactions. 点此查看雅法近期交易:

- Flexion: Approved Osteoarthritis-related Knee Pain Therapy Licensing-out


- Tarveda: Ph1 Oncology Asset Licensing-out including a Strategic Investment


Transaction Overview 交易概览

- Rhizen Pharmaceuticals (Rhizen Pharmaceuticals, S.A.) signs exclusive license agreement with Curon Biopharma (Curon Biopharmaceutical Limited) for the development and commercialization of Tenalisib in Greater China

- Rhizen宣布与同润生物医药在大中华区签订处于临床阶段的磷脂酰肌醇3-激酶双重抑制剂Tenalisib的许可协议

- Shanghai YAFO Capital (YAFO Life Science) acted as the exclusive financial advisor on this transaction for Rhizen

- 上海雅法资本(雅法全球医疗)在此次交易中担任Rhizen公司的独家财务顾问

- License agreement provides Rhizen with up to $149.5 million upfront payment and milestones, plus double-digit royalties on annual net sales of Tenalisib

- Rhizen将获得最高1.495亿美元的授权许可首付款和里程碑付款,以及额外的二位数销售授权费。

Press Release Link:


About The Asset 交易资产介绍

Tenalisib (RP6530) is a highly selective, next-generation, orally active, dual PI3K delta and gamma inhibitor, that is currently in Phase 2 clinical development for hematological malignancies. Tenalisib has been granted US FDA Fast Track & Orphan-Drug Designations for treatment of relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma (R/R PTCL and R/R CTCL).


About Rhizen Pharmaceuticals S.A.

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer and inflammatory diseases. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland.


About Curon Biopharmaceutical 同润生物医药

Curon Biopharmaceutical, founded in June 2018, is a biopharma company with facility in Shanghai focusing on developing next generation anti-cancer therapies. It completed a $150 million USD Series A financing led by 6 Dimensions Capital, Boyu Capital, and Temasek. With its internationally experienced senior executive management team, Curon Biopharma currently holds multiple promising novel cancer immuno-therapeutic agents in its pipeline and is committed to bring next generation cancer immunotherapies to patients. Curon strives to accelerate its pipeline assets clinical development, further expand its portfolio through in-licensing and other forms of collaboration with biotech and pharmaceutical companies around the world to bring more effective treatment options to patients.


About YAFO Life Science 雅法全球医疗

YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and medtech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com

雅法全球医疗(YAFO Life Science)是雅法资本旗下的医疗大健康部门,专注于帮助具有“中国角度”的海外医药、医疗器械企业在中国的融资、授权和战略合作;为中国医疗企业提供产品全球授权、海外市场研究服务,寻找海外投资并购标的,及产品商业合作。雅法全球医疗核心合伙人团队均为华尔街资深投行人士或具有跨国药企工作经验;雅法庞大的海外的区域合伙人团队,均具20+年医药行业及交易经验,覆盖美国、日本 、欧洲等主要全球医药创新区域。项目合作请联系:黎琦 | BD Director | 13621979227 | qli@yafocapital.com

YAFO Upcoming Events - ACCESS CHINA WINTER EVENT (Jan. 2021, JPM)

Please email Wendi Xiang, wxiang@yafocapital.com, if you want to present or attend our winter partnering event.


项目合作请联系:黎琦,BD Director,qli@yafocapital.com